1	
2	
3	
4	
5	Myocardial-derived small extracellular vesicles spontaneously
6 7	released from living myocardial slices under biomimetic culture conditions regulate contractility and cardiac remodelling
8 9	L. Nicastro, A. Lal, A. Kyriakou, S. Kholia, R. Nunez Toldra, B. Downing, F. Kermani, M. Anwar, F. Martino, D. Chokron, P. Sarathchandra, M. Sarkar, C. Emanueli, C.M. Terracciano [*]
10	National Heart & Lung Institute, Imperial College London, London, UK
11	
12	
13	Short title: Myocardial -derived sEVs affect remodelling of failing hearts
14	
15	
16	
17	
18	*Corresponding author:
19 20 21 22 23 24 25 26 27	Prof. Cesare M. Terracciano Imperial College London, NHLI ICTEM building Hammersmith Campus, Du Cane Road, London W12 ONN, UK Email: <u>c.terracciano@imperial.ac.uk</u>

Nicastro et al.

Myocardial -derived sEVs affect remodelling of failing hearts

28

29 Abstract

BACKGROUND: 30

Small extracellular vesicles (sEVs) released in the cardiac microenvironment are reported to 31 regulate cardiac remodelling, partially via microRNA transfer. Harvesting sEVs produced 32 exclusively from the myocardium remains challenging and a solid research platform for sEV 33 34 cardiovascular testing needs to be established. Organotypic living myocardial slices (LMS) allow to mimic cardiac disease and to record electrophysiological responses to biological 35 and pharmacological stimuli. This study aims at understanding how cardiac sEVs obtained 36 from donor and failing human LMS and rat LMS under physiological or heart failure-37 mimicking conditions impact myocardial function and remodelling. 38

39

40 **METHODS & RESULTS:**

Human LMS were obtained from the left ventricle (LV) of human donor non-failing and end-41 stage failing hearts and cultured at 2.2 µm sarcomere length (SL). Rat LV LMS from healthy 42 Sprague-Dawley rats were cultured at a preload of 2.2 or 2.4 μ m SL, to recapitulate 43 physiological load and overload, respectively. Following 48-hours biomimetic culture, sEVs 44 45 were isolated from the culture media by size exclusion chromatography and characterized 46 for their size, concentration, and expression of exosome markers. LMS from human failing hearts presented impaired contractility (P<0.05 vs donor-LMS), which was improved by 47 application of donor heart-derived sEVs at 15 and 20% stretch. Whilst rat overloaded sEVs 48 did not alter the force production of physiological LMS, physiological sEVs significantly 49 increased the active force and decreased their passive force. In rat LMS, 1x10⁸ physiological 50 EVs/slice restored the contractility of overloaded slices, reduced apoptosis, fibrosis-related 51 gene expression and promoted angiogenesis. microRNAs analysis showed significant 52 upregulation of miR-23a-3p and miR-378a-3p in rat physiological sEVs. Finally, to test 53 whether sEVs have a direct effect on cardiomyocytes, we applied sEVs on cultured induced 54 55 pluripotent stem cell-derived cardiomyocytes (iPSC-CMs). sEVs did not affect the contractility of iPSC-CM monoculture but increased the contractility of iPSC-CM co-cultured 56 with human microvasculature endothelial cells (MVECs). 57

58

CONCLUSIONS: 59

60 Cardiac sEVs isolated from healthy hearts increase the contractility of failing LMS. This effect is associated with, and possibly brought about by, a combination of inhibition of apoptosis, 61 reduction of fibrosis and increased microvascular density, and could involve the transfer of 62 sEV-microRNA into myocardial cells. Our data support the hypothesis that the sEV inotropic 63 action is mediated by endothelial cells. 64

Nicastro et al.

Myocardial -derived sEVs affect remodelling of failing hearts

Introduction 65

Increased mechanical load caused by either excessive pressure or volume in the left 66 ventricle is an important driver of cardiac remodelling. Multiple changes take place during 67 68 remodelling caused by mechanical overload, such as development of hypertrophy, myocardial cells death, fibrosis, and blood vessel rarefaction. Over time these changes lead 69 to ventricular dysfunction and ultimately heart failure¹. 70

During both physiology and disease, cell-cell communication is responsible for driving 71 cellular and molecular changes to respond to changes in the environment ^{2,3}. Numerous 72 mechanisms of cell-cell communication, from direct contact to the release of soluble 73 paracrine and endocrine factors, have been extensively investigated and are known to be 74 75 important mediators of both cardiac homeostasis and remodelling.

76 Extracellular vesicles (EVs) encompass several types of nanosized and micro-sized vesicles 77 with a lipid bilayer membrane and bioactive cargoes, including nucleic acids, proteins, lipids and metabolites⁴. Small EVs (sEVs), also known as exosomes, have been already recognized 78 as important mediators of intercellular and extracellular communications in the 79 cardiovascular system⁵. Both proteins and microRNAs (miRNAs) have been found to mediate 80 cellular responses induced by sEVs, including cardiac remodeling and cardiac protection^{6, 7, 8,} 81 ⁹. Despite the interest for sEVs in cardiovascular research, the understanding of the role of 82 endogenous cardiac sEVs in the local microenvironment has been so far hindered by the lack 83 of appropriate research models. Previous in vitro and in vivo studies have adopted sEVs 84 85 prepared from either complex and non-cardiac specific samples, such as the human plasma¹⁰, or cultured cells, which are unable to recapitulate the complexity of the 86 myocardium, making most studies of low translational value². 87

88 Living myocardial slices (LMS) are 300 µm thin layers of ventricular myocardial tissue that can be obtained from human heart of donors and heart failure patients and, also, from 89 different small and large animal species ¹¹. LMS not only retain the multi- and hetero-90 91 cellular composition, the electrophysiology, and the extracellular matrix of the adult 92 myocardium, but also possess the ability to long term culture while performing physiological functions, the ability to be manipulated in a specific and controlled manner by various 93 stimuli, and the capacity to be studied for cellular and molecular mechanisms ^{11–13}. 94 Noteworthy, pathological stimuli known to affect cardiac remodelling and sEVs biology, such 95 as mechanical overload, can be reliably reproduced in LMS^{14–16}. 96

In this study, we have employed LMS to isolate and characterize sEVs released from human 97 98 donors and failing hearts. We have complemented the human studies with analyses of rat LMS subjected to different degrees of mechanical load to investigate the effects of cardiac-99 derived sEVs on the regulation of cardiac contractility and structural and molecular 100 overload-induced myocardial remodelling. 101

Methods 102

Methods are described in detail in the Supplemental Material. 103

Ethical statements for the use of human and rat hearts 104

perpetuity. All rights reserved. No reuse allowed without permission.

Nicastro et al.

Myocardial -derived sEVs affect remodelling of failing hearts

Human failing hearts were obtained from the NIHR Cardiovascular Biomedical Research Unit
 at the Royal Brompton and Harefield NHS Foundation Trust and Imperial College London.
 The study was approved by a UK institutional ethics committee (NRES ethics number for
 biobank samples: 09/H0504/104 + 5; Biobank approval number: NP001-06-2015 and
 MED CT 17 079) and Imperial College London.

Human donor hearts were obtained from the NHS Blood and Transplant INOAR program (IRAS project ID: 189069) approved by the NHS Health Research Authority, in accordance with the Governance Arrangements for Research Ethics Committees. This study is fully compliant with the Standard Operating Procedures for Research Ethics Committees in the UK. Informed consent was obtained from each patient/family involved in this study.

All experiments performed on animals were approved by the UK Home Office, in accordance 115 with the United Kingdom Animals (Scientific Procedures) Act 1986 and Amendment 116 Regulations 2012; killing procedures were performed in accordance with the established 117 guidelines of the European Directive on the protection of animals used for scientific 118 purposes (2010/63/EU). The investigation conforms to the Guide for the Care and Use of 119 Laboratory Animals published by the US National Institutes of Health (NIH Publication No. 120 121 85-23, revised 1985) and to the principles outlined in the Declaration of Helsinki (Br Med J 1964; ii: 177). 122

123 Statistical analysis

All data are expressed as mean \pm standard error of the mean. Data were analysed using 124 GraphPad Prism 9 software. To assess normality, Shapiro-Wilk's test was used. For multiple 125 groups comparisons of normally distributed data where unpaired samples were used, such 126 as contractility data in physiological, overloaded and EVs treated LMS at different stretch 127 128 increments, two-way ANOVA was used, followed by Tukey's multiple comparison test. For 129 multiple groups comparison of normally distributed data where paired samples were used, such as contractility data in human failing LMS treated with donor sEVs and untreated, 130 multiple paired t-test was used, as control and treated preparation were handled in parallel. 131 To measure sEVs particle size distribution in human and rat samples, the area under the 132 curve for the particle size distribution was calculated, and an unpaired 2-tail t-test 133 performed, using the average concentration, SEM and N number for the respective 134 conditions, which were previously calculated in the area under the curve analysis. For 135 experiments assessing remodelling aspects in physiological, overloaded and EVs treated 136 LMS, one-way ANOVA was used followed by Tukey's multiple comparison test. Kruskal 137 138 Wallis test and Dunn's multiple comparison test were used when data were not normally distributed. 2-tailed student t-test was used to compare the treated versus non-treated 139 groups in iPSC-CMs-only and co-culture experiments. 140

141

142 Results

143 Active force in human failing LMS is significantly lower compared with human donor LMS

Nicastro et al.

Myocardial -derived sEVs affect remodelling of failing hearts

All human donor and failing LMS were cultured at a SL of 2.2 µm. To investigate 144 contractility, we performed a force-stretch relationship experiment after 48 hours of 145 culture. As shown in Figure 1 A and B, donor LMS generated a larger force upon stimulation 146 compared with failing LMS; there was no significant change in passive force (Figure 1C). 147

Human failing sEVs are more abundant compared to human donor EVs 148

Cardiac sEVs were extracted from the supernatant of donor and failing LMS culture. The sEV 149 particle-size distribution and concentration were analysed by Nanoparticle Tracking 150 151 Analysis. The analysis showed a higher concentration of sEVs/ml from the failing heart, 152 compared to the donor heart (Figure 1 D). The sEV identity was confirmed by tetraspanin (CD63, CD81 and CD9) chips for sEV capture and imaging on the ExoView[™] R100 imaging 153 platform (NanoView Biosciences). As shown in Figure 1 E, the human sEVs expressed all 154 three tetraspanins ¹⁷, in different quantities, with CD81 being the most abundant 155 (Supplementary figure 1 B). Transmission electron microscopy with immunogold-labelled 156 antibodies targeting the human CD63 tetraspanin marker further confirmed the successful 157 enrichment of sEVs secreted by human LMS (Figure 1 F). 158

159

160 Human sEVs released by the donor LMS increase the active force produced by human 161 failing LMS

Given the biological relevance of cardiac sEVs isolated from the human donor LMS, we 162 sought to investigate whether these sEVs affect cardiac contractility of human failing LMS. 163 We observed that failing human LMS cultured with 10⁹ donor sEVs, which corresponded to 164 the number of particles released from an individual human donor LMS after 48 hours, had 165 increased contractility compared with their untreated counterpart (Figure 2 A). In fact, the 166 active force of failing LMS treated with donor sEVs was significantly higher at 15 and 20% 167 stretch compared with non-treated LMS, whilst no change in passive force was observed 168 (Figure 2 B and C). 169

170 Active force production in rat physiological LMS is higher compared with overloaded LMS

To recreate physiological load and overload, we stretched rat slices uniaxially in order to 171 obtain a SL of 2.2 and 2.4 µm, respectively (Figure 3 A, from ¹⁴). Following 48 hours of 172 culture, we observed that physiological and overloaded LMS exhibited a different contractile 173 phenotype (Figure 3 B). Figure 3 C shows that physiological LMS generated significantly 174 higher active force from 5 to 25% stretch, compared with the overloaded LMS. The passive 175 force did not change significantly between the two conditions (Figure 3 D). 176

177 Rat overloaded LMS secrete an equal amount of sEVs to physiological LMS but the sEVs 178 contain more proteins

A particle-size distribution analysis revealed a similar concentration of sEVs released from 179 180 overloaded LMS compared to physiological LMS (Figure 3 E and supplementary figure 1 A). However, measurements of internal protein content of sEVs revealed a higher amount of 181 protein in the sEVs from overloaded LMS, when compared to physiological LMS (Figure 3 F). 182 Electron microscopy with CD63 immunogold labelling confirms the presence of rat sEVs 183

perpetuity. All rights reserved. No reuse allowed without permission.

Nicastro et al.

Myocardial -derived sEVs affect remodelling of failing hearts

184 (Figure 3 G). Given the more immediate availability of rat hearts, the following functional, 185 structural, and molecular studies were performed on rat LMS and rat LMS-derived sEVs.

186 Physiological cardiac sEVs increase the active force and decrease the passive force of 187 physiological LMS

Both physiological and overloaded sEVs were applied on rat physiological LMS to assess 188 whether sEVs would mediate changes in contractility on healthy tissue (Figure 4 A). Force-189 stretch relationship of physiological LMS treated with either PBS vehicle, physiological sEVs 190 191 or overloaded sEVs revealed that physiological sEVs increase the active force of physiological LMS at 25% and 30% stretch (Figure 4 B) and decrease the passive force from 0 192 to 20% stretch (Figure 4 C). However, the application of overloaded sEVs on physiological 193 LMS had no significant effect on the production of both active and passive force, compared 194 to untreated physiological LMS (Figure 4 B and C). 195

Physiological cardiac sEVs increase the active force of overloaded LMS in a dose-response manner

To assess the functional effect of rat physiological sEVs on the overloaded LMS, concentrations ranging from 10^7 to 10^{10} were tested (Figure 4 D). We observed that the minimum amount of sEVs per LMS required to achieve a significant increase in active force was 1×10^8 sEVs (Figure 4 E). However, no significant difference was observed in the passive force of overloaded rat LMS treated with physiological sEVs (Figure 4 F). The following structural and molecular experiments to assess cardiac remodelling were performed using 1×10^8 sEVs.

Application of physiological cardiac sEVs does not affect the size of cardiomyocytes in overloaded LMS

In a condition of volume overload, eccentric hypertrophy develops, where the cardiomyocytes elongate, and sarcomeres are added in series ¹⁸. In our model of uniaxial mechanical overload, we saw a significant elongation of the cardiomyocytes, compared to the physiological condition (Supplementary figure 2 A). This resulted in an overall increase of the cardiomyocytes area, whilst no difference was observed in the width (Supplementary Figure 2 B and C). The application of physiological sEVs on overloaded slices did not change cell size (Supplementary Figure 2 D).

214 Application of physiological cardiac sEVs attenuates the transcriptional expression of 215 profibrotic genes in overloaded LMS

The development of fibrosis following mechanical overload is an important determinant of 216 cardiac contractility¹⁹. Production and deposition of collagens in the ECM and proliferation 217 of stromal cells are crucial factors in the identification of cardiac fibrosis. Therefore, we first 218 219 examined the amount of Collagen I and Vimentin deposition through immunostaining (Figure 5 A); no difference was observed between physiological and overloaded LMS (Figure 220 5 B and C, respectively). The expression of Collagen I was also studied at protein level, along 221 with the protein α -smooth muscle actinin (α -SMA), to assess fibroblasts activation. No 222 significant change was observed in the expression of Collagen I (Figure 5 D) and α -SMA 223

Nicastro et al.

Myocardial -derived sEVs affect remodelling of failing hearts

224 (Figure 5 E) between physiological and overloaded slices. Likewise, the application of 225 physiological sEVs on overloaded slices did not have any effect on fibrosis development at 226 either structural or protein level. However, when we analysed expression of some of the 227 fibrosis-related genes by q-RT-PCR, we observed increased levels of α-SMA, Fibronectin, 228 TGF- β , Collagen I and SMAD3 in the overloaded LMS, compared with physiological. 229 Application of physiological sEVs on overloaded slices prevented/reversed the activation of 230 Fibronectin, TGF- β and SMAD3 (Figure 5 F).

231 Application of physiological cardiac sEVs reduces cell death in overloaded LMS

To assess cell death, another possible determinant of reduced cardiac contractility ²⁰, we 232 first measured the level of cleaved PARP-1. PARP-1 is cleaved when it gets activated during 233 apoptosis²¹. Cleaved PARP-1 was increased in overloaded LMS compared with physiological 234 LMS. Moreover, upon application of physiological sEVs, the cleavage of PARP-1 was reduced 235 to almost physiological levels (Figure 6 A). Bcl-2 is a potent pro-survival protein. Whilst its 236 expression was maintained at basal level in physiological and overloaded slices, the level of 237 Bcl-2 increased following application of sEVs on overloaded LMS. These data suggest that 238 239 sEVs activate pro-survival pathways in the slices subjected to increased mechanical load 240 (Figure 6 B).

241 Cell death in the LMS was further investigated by TUNEL staining. Transversal LMS 242 cryosections showed increased TUNEL positive nuclei mostly on the surface of overloaded 243 LMS, compared with physiological LMS. Application of physiological sEVs on overloaded LMS 244 reduced the abundance of TUNEL positive nuclei to almost physiological levels (Figure 6 C).

Application of physiological cardiac sEVs reduces microvascular rarefaction in overloaded LMS

Heart failure is associated with microvascular rarefaction^{22,23}. In our study, Isolectin B4 staining confirmed reduced microvascular density in the overloaded LMS compared with physiological slices. Application of physiological sEVs in overloaded slices partially prevented this phenomenon (Figure 7 A) and increased the mRNA expression of VEGF-A, a prototypical proangiogenic and angiocrine factor (Figure 7 B).

Exogenous cardiac sEVs preferentially localize around the nuclei of non-cardiomyocytes in the recipient LMS

We first performed sEV incorporation studies at 1, 24 and 48 hours using ExoGlow-stained 254 255 sEVs to understand the time course of sEV uptake. We observed the presence of sEVs on the 256 surface of LMS at 1- and 24-hours, but this was reduced at 48-hours (Supplementary Figure 3 A), suggesting that after 48 hours of incubation, sEVs are mostly internalised by the LMS. 257 To assess the biodistribution of sEVs, we performed experiments using the 24-hours 258 timepoint, to quantify the presence of sEVs on the cells surface at their maximum visibility. 259 260 We observed that sEVs were preferentially localized around the nuclei of noncardiomyocytes: 19.3% of the total nuclei of vimentin-positive cells, and only 5.76% of α -261 actinin-positive cells were co-localised with sEVs (Supplementary Figure 3 B). 262

Nicastro et al.

Myocardial -derived sEVs affect remodelling of failing hearts

Physiological cardiac sEVs contain higher level of microRNA-378a-3p and -23a-3p in 263 comparison with pathological sEVs 264

To investigate differences in miRNAs cargo between physiological and overloaded rat sEVs, 265 266 we performed a miRNA array to assess the expression of 372 miRNAs which are conserved between rat and human species. We found two miRNAs (miR), miR-378a-3p and hsa-miR-267 23a-3p, to have higher expression in physiological compared with overloaded sEVs. By 268 contrast, miR-16-5p and miR-346, were significantly increased in the overloaded sEVs 269 (Supplementary Figure 4 A and B). We focussed on the upregulated miRNAs in physiological 270 271 sEVs, as these could directly repress the expression of their target genes in overloaded LMS. miRNA gPCR analysis confirmed the upregulation of miR-378a-3p and miR-23a-3p in 272 physiological sEVs compared with overloaded sEVs (Supplementary Figure 4 C and D). 273

Bioinformatics analysis reveals potential mRNA targets of miR-378a-3p and miR-23a-3p 274 275 that are increased in cardiomyocytes extracted from overloaded LMS

We performed a bioinformatics analysis to find potential target genes for miR-378a-3p and 276 hsa-miR-23a-3p. Predicted targets of miR-378a-3p and hsa-miR-23a-3p were cross-277 278 referenced with genes that were significantly differentially expressed in cardiomyocytes 279 isolated from overloaded LMS, compared to physiological (Supplementary Figure 5 A). Six target genes, Gadd45g, Slc4a11, Xirp2, Dusp13, Usp13 and Triadin, were identified, which 280 were overexpressed in overloaded cardiomyocytes and regulated by miR-378a-3p and hsa-281 miR-23a-3p (Supplementary Figure 5 B and C). Pathway analyses performed on these genes 282 283 revealed their possible involvement in cardiac contractility and apoptosis (Supplementary Figure 5 D). 284

Physiological cardiac sEVs do not regulate the contractility of human cardiomyocytes 285 monocultures. 286

287 Given the interplay between different cardiac cells in the LMS, it is challenging to assess whether cardiomyocytes are directly affected by sEVs to increase cardiac contractility. To 288 address this issue, we employed human iPSC-CMs that express the calcium indicator 289 GCaMP6f²⁴, to simultaneously assess the impact of cardiac sEVs on calcium handling and 290 291 cardiomyocyte contractility (Figure 10 A and B). iPSC-CMs were seeded on 7 mm diameter MatTek dishes at a density of 80,000 cells per dish for 48 hours and treated with 10⁹ sEVs or 292 PBS control. Calcium handling and contractility were assessed and compared between sEVs-293 treated and untreated (PBS only) iPSC-CMs. There was no significant difference in the 294 295 amplitude of calcium transients between sEV-treated iPSC-CMs and controls (Figure 10 C). 296 Nevertheless, the iPSC-CMs time to peak of the calcium transients was increased after sEV-297 treatment (Figure 10 D). The time to 50% and 80% decay remained unchanged between the 2 conditions (Figure 10 E and F). Likewise, the amplitude of iPSC-CM contractility was not 298 different in sEV-treated and control iPSC-CMs (Figure 10 G). 299

Physiological cardiac sEVs increase contractility of IPSC-CM co-cultured with endothelial 300 301 cells

Nicastro et al.

Myocardial -derived sEVs affect remodelling of failing hearts

Given the increased VEGF-A and vascular response observed in overloaded LMS treated with 302 physiological cardiac sEVs (Figure 7 A and B), and the prevalent non-CM distribution of 303 exogenous sEVs in recipient LMS (supplementary Figure 3 B), we hypothesised the 304 importance of endothelial cells for the CM response to sEVs. We therefore co-cultured 305 iPSC-CMs with human coronary microvascular endothelial cells (MVECs) before sEVs 306 application (Figure 10 H and I). Physiological cardiac sEVs did not affect calcium handling 307 parameters compared to control (Figure 10 J-M). However, cardiac sEV increased the 308 contractility of iPSC-CM co-cultured with MVEC (Figure 10 N). 309

310 Discussion

We report the successful isolation and characterisation of sEVs secreted from the 311 ventricular myocardium of human failing and donor healthy hearts and from rat LMS 312 cultured under physiological and overloaded conditions. Our protocols open unprecedented 313 possibilities for the characterization of the cardiac sEVs in the cardiac microenvironment. 314

This study has demonstrated that cardiac sEVs released from the human donor hearts 315 increase the contractility of failing LMS. Moreover, rat physiological sEVs increase 316 contractility of both physiological and overloaded LMS, at a minimum concentration of 10⁸ 317 318 particles/LMS. In contrast, sEVs released from the rat overloaded LMS had lost the capacity to regulate contractility. 319

We have showed that overload reduces LMS contractility, increases the expression of 320 profibrotic genes, reduces cell survival and induces microvascular rarefaction, simulating the 321 feature of failing myocardium. Importantly, these pathogenic features are repressed by 322 stimulating the LMS with rat physiological cardiac sEVs, thus suggesting that sEVs released 323 from healthy hearts contribute to preventing and possibly reversing, pathological cardiac 324 325 remodelling.

HF with reduced ejection fraction (HFrEF) is characterised by lower muscle contractility. In 326 clinical cases of HF, there is a downward shift in the Frank-Starling curve, which correlates 327 with the inability of the heart to work effectively ²⁸. LMS are an ideal *ex vivo* platform to 328 study myocardial contractility because they retain the electrophysiology and multicellularity 329 of the adult myocardium ²⁹. Here we show that human failing LMS shifted the Frank Starling 330 curve downwards compared with donor LMS, in accordance with what is observed clinically 331 30,31 332

By applying different degrees of mechanical load on rat LMS, we were able to induce a 333 distinct contractile phenotype, similar to what was observed in the human slices. This 334 finding has been previously reported by us in ^{14,32}. For instance, we experimentally 335 determined the best SL to culture LMS for 24 hours, and found that slices cultured at 2.2 µm 336 maintained the same viability, gene expression and minimal change in force compared to 337 fresh slices, where contractility was measured immediately after slicing ¹⁴. We reported a 338 significant difference in the amplitude of maximum contractility between rat slices cultured 339 at 2.2 and 2.4 µm after 48 hours. The significant decrease in force produced by the 340 overloaded slices was associated with an increase in Collagen I deposition and the 341 overexpression of major profibrotic genes ³². While 48-hour culture might not be sufficient 342

Nicastro et al.

Myocardial -derived sEVs affect remodelling of failing hearts

to induce a complete remodelling of the LMS in vitro, the rat overloaded LMS recapitulate 343 several features of human failing myocardium. 344

Native sEVs are considered for their potential to regulate cardiac homeostasis. This is in line 345 with the knowledge that sEVs isolated from specific cardiac cell types contain cargoes that 346 can confer cardioprotection in a damaged heart ³³; however, the effects of cardiac sEVs 347 released from the myocardial tissue remain untested. In this study, we demonstrate that 348 LMS release sEVs; we show the ability of healthy sEVs derived from the human and rat 349 hearts to restore contractility and partially reverse/prevent remodelling after cardiac 350 damage ^{35–38}. 351

In our study, despite observing a significant difference in sEV release between human failing 352 and donor LMS, we showed that there was no difference in the concentration of sEVs 353 released by either rat overloaded or physiological LMS after 48 hours culture. However, 354 overloaded LMS-derived sEVs did not significantly affect the production of either active or 355 passive force in physiological slices, in clear contrast with physiological sEVs, suggesting that 356 the formulation of the sEVs derived from physiological and pathological is different. In line 357 with this, we recorded different levels of total protein content between overloaded and 358 359 physiological sEVs.

Several studies have shown that sEV actions are mediated by miRNA transfer ^{39,40}. 360 Therefore, the beneficial effects of cardiac sEVs may be mediated by miRNA transfer. In line 361 with this hypothesis, we found increased expression of miR-378a-3p and hsa-miR-23a-3p in 362 363 the physiological cardiac sEVs when compared with the sEV from rat overloaded LMS. These miRNAs have been previously shown to repress cardiac hypertrophy ⁴¹ and apoptosis ⁴² and 364 to promote angiogenesis ⁴⁵. A limitation of our miRNA array approach is that it contained a 365 limited number of miRNAs selected for their conservation between humans and rats. 366 367 Alternative miRNA candidates might emerge in future studies based on RNA-sequencing approaches. 368

A miRNA canonical mechanism of action is to repress the expression of a pool of targeted 369 genes acting at post-transcriptional level by binding to the 3'UTR of mRNAs ⁴⁶. In line with 370 this, bioinformatic target prediction revealed that potential target genes of miR-378a-3p 371 and hsa-miR-23a-3p were involved in the regulation of cardiac contractility and apoptosis of 372 cardiomyocytes. 373

Excessive mechanical preload of the heart results in the development of eccentric 374 hypertrophy, where cardiomyocytes elongate through the addition of sarcomeres in series 375 ⁴⁷. In our model of mechanical overload, we observed a significant elongation of 376 cardiomyocytes compared to the physiological counterpart. The addition of sarcomeres in 377 series leads to a decrease in force being generated by the cardiomyocytes, as to reach an 378 optimal SL, longer cardiomyocytes may need to be stretched more, compared to shorter 379 cardiomyocytes containing less sarcomeres ⁴⁸. 380

In our study, we found that after 48 hours of culture under overloaded conditions, the 381 process of fibrosis activation is only initiated at transcriptional level, with no significant 382 changes at protein and structural level. However, physiological sEVs were able to inhibit the 383

Nicastro et al.

Myocardial -derived sEVs affect remodelling of failing hearts

overexpression of the major pro-fibrotic genes in overloaded slices. A previous study on 384 fibrosis conducted on LMS showed that, although there was a significantly higher Collagen I 385 deposition in overloaded slices after 48 hours compared with the physiological controls, the 386 difference in the amount of stromal cells proliferation on the slices was unchanged¹⁵. 387 Moreover, the changes in Collagen I were only seen with immunofluorescence staining and 388 could not be detected by western blot analysis. 389

The cleavage of PARP-1 is a hallmark of cell death ⁴⁹. In our study, we observed a significant 390 increase in cleaved PARP-1 in the overloaded slices compared with the physiological LMS. 391 392 TUNEL staining revealed that cell death was prevalently localized on the surface of the myocardial slices. During LMS preparation, the blade cutting along the surface of the tissue 393 damages ~3% of the total LMS cells, and only on the surface of the slice, leaving the rest of 394 the preparation intact ¹¹. We speculate that surviving cells on the LMS surface are more 395 fragile and sensitive to the detrimental actions of overload. Physiological sEVs were able to 396 inhibit the process of cell death on overloaded slices. However, because changes in cell 397 death were limited to the LMS surface, is unlikely that prevention of cell death by the 398 healthy sEVs is the only contributor to the increase in contractility produced by these sEVs. 399

Microvessels rarefaction is a hallmark of cardiac remodelling and reportedly contributes to 400 HF with preserved ejection fraction (HFpEF)⁵⁰. Microvessels are tasked not only to 401 constantly deliver oxygenated blood and nutrients to cardiomyocytes, but also act as a 402 403 source of paracrine regulatory molecules that help in the modulation of cardiac contractility ⁵¹. In the overloaded slices, we observed a significant loss in microvessels. It is worth noting 404 405 that vessels are not perfused in LMS, therefore regulation of cardiomyocyte contractility is likely to occur through direct contact and/or paracrine interactions. VEGF was maintained at 406 basal levels in physiological and overloaded conditions but, upon application of sEVs, these 407 408 levels raised significantly, suggesting that sEVs may contain cargoes that promote the 409 production of VEGF. We found that most of the sEVs are taken up by the noncardiomyocytes. This could indicate an indirect effect on contractility, mediated by other 410 cell types other than CMs, in particular ECs. 411

To confirm whether sEVs have a direct effect on CM contractility, we analysed calcium 412 413 handling and contractility of IPSC-CMs monoculture. Physiological sEVs did not affect the contractility of iPSC-CMs nor the amplitude of calcium transients, suggesting that 414 physiological sEVs may act on other cell types. Given the effect of physiological sEVs on LMS 415 microvessels, we co-cultured iPSC-CMs with MVECs. In the co-culture experiments, despite 416 no change in the calcium handling parameters, we observed a significant increase in 417 418 contractility when physiological sEVs were applied. This suggests that changes in IPSC-CM 419 contractility are: i) mediated by the effect of sEVs on ECs, and ii) due to changes in myofilament sensitivity to calcium. There are few limitations of these cellular experiments: 420 although iPSC-CMs lines have been extensively used in cardiovascular research to 421 422 recapitulate disease models, these cells are still very different from adult CMs, due to their relatively immature phenotype, and therefore it might not be a fully representative model 423 to describe the changes in contractility that occur in the LMS ⁵². Moreover, in our study 424

perpetuity. All rights reserved. No reuse allowed without permission.

Nicastro et al.

Myocardial -derived sEVs affect remodelling of failing hearts

- 425 mechanical load is a major determinant of remodelling, but overload could not be recreated426 in iPSC-CMs.
- 427 If these results are extrapolated to the LMS model, whereby sEVs had a significant effect on 428 contractility, preserved microvessel density and increased VEGF production, they may 429 suggest that the beneficial effects of sEVs are indirect and mediated, at last in part, by ECs. It 430 could be speculated that once sEVs (and their associated miRNAs) are taken up by ECs, they
- 431 would release factors (such as VEGF) that improve CM contractility 5^{3} . As example, miR-
- 432 378a-3p was already shown to indirectly increase VEGF-A in skeletal muscles 54 .

433 Conclusions

434 Myocardial-specific sEVs from healthy human and rat hearts restore contractility and 435 reverse/prevent remodelling of failing myocardium. The effects on contractility could be 436 mediated by inhibition of cell death, inhibition of pro-fibrotic gene pathways or by 437 preservation of blood vessels, or a combination of them, via indirect heterocellular 438 interactions. The miRNA signature of the healthy sEVs may contribute to explain these 439 effects. Our findings support the importance of sEVs in physiology and disease, and their 440 potential utilisation in the treatment of cardiovascular disease.

441 Acknowledgements:

442 We would like to thank Steve Rothery for the support with confocal microscopy, Fatemen

Kermani for the gift of MVECs and Danya Agha-Jaffar for the support with the human tissue.

444 We are grateful to the British Heart Foundation for financial support (FS/19/57/34894).

445

446 Bibliography

- Katz AM. Maladaptive growth in the failing heart: the cardiomyopathy of overload.
 Cardiovasc Drugs Ther. 2002;16:245–249.
- Martins-Marques T, Hausenloy DJ, Sluijter JPG, Leybaert L, Girao H. Intercellular
 Communication in the Heart: Therapeutic Opportunities for Cardiac Ischemia. *Trends Mol Med*. 2021;27:248–262.
- 452 3. Tirziu D, Giordano FJ, Simons M. Cell Communications in the Heart. *Circulation*.
 453 2010;122:928–937.
- Jeppesen DK, Zhang Q, Franklin JL, Coffey RJ. Extracellular vesicles and nanoparticles:
 emerging complexities. *Trends Cell Biol*. 2023;33:667–681.
- 5. Davidson SM, Boulanger CM, Aikawa E, Badimon L, Barile L, Binder CJ, Brisson A, Buzas E,
 Emanueli C, Jansen F, Katsur M, Lacroix R, Lim SK, Mackman N, Mayr M, Menasché P,
 Nieuwland R, Sahoo S, Takov K, Thum T, Vader P, Wauben MHM, Witwer K, Sluijter JPG.
 Methods for the identification and characterization of extracellular vesicles in cardiovascular
 studies: from exosomes to microvesicles. *Cardiovasc Res.* 2023;119:45–63.
- 461 6. Bellin G, Gardin C, Ferroni L, Chachques J, Rogante M, Mitrečić D, Ferrari R, Zavan B. Exosome
 462 in Cardiovascular Diseases: A Complex World Full of Hope. *Cells*. 2019;8:166.

perpetuity. All rights reserved. No reuse allowed without permission.

Nicastro et al.

Myocardial -derived sEVs affect remodelling of failing hearts

463 7. Bang C, Batkai S, Dangwal S, Gupta SK, Foinquinos A, Holzmann A, Just A, Remke J, Zimmer K, 464 Zeug A, Ponimaskin E, Schmiedl A, Yin X, Mayr M, Halder R, Fischer A, Engelhardt S, Wei Y, Schober A, Fiedler J, Thum T. Cardiac fibroblast-derived microRNA passenger strand-enriched 465 exosomes mediate cardiomyocyte hypertrophy. Journal of Clinical Investigation. 466 2014;124:2136-2146. 467 8. 468 Zheng D, Huo M, Li B, Wang W, Piao H, Wang Y, Zhu Z, Li D, Wang T, Liu K. The Role of 469 Exosomes and Exosomal MicroRNA in Cardiovascular Disease. Front Cell Dev Biol. 2021;8. 470 9. Vicencio JM, Yellon DM, Sivaraman V, Das D, Boi-Doku C, Arjun S, Zheng Y, Riquelme JA, 471 Kearney J, Sharma V, Multhoff G, Hall AR, Davidson SM. Plasma Exosomes Protect the 472 Myocardium From Ischemia-Reperfusion Injury. J Am Coll Cardiol. 2015;65:1525–1536. 473 10. Pant S, Hilton H, Burczynski ME. The multifaceted exosome: Biogenesis, role in normal and 474 aberrant cellular function, and frontiers for pharmacological and biomarker opportunities. 475 Biochem Pharmacol. 2012;83:1484–1494. 476 11. Watson SA, Scigliano M, Bardi I, Ascione R, Terracciano CM, Perbellini F. Preparation of viable 477 adult ventricular myocardial slices from large and small mammals. Nat Protoc. 2017;12:2623-478 2639. 12. 479 Perbellini F, Liu AKL, Watson SA, Bardi I, Rothery SM, Terracciano CM. Free-of-Acrylamide 480 SDS-based Tissue Clearing (FASTClear) for three dimensional visualization of myocardial 481 tissue. Sci Rep. 2017;7:5188. 482 13. Perbellini F, Watson SA, Scigliano M, Alayoubi S, Tkach S, Bardi I, Quaife N, Kane C, Dufton NP, Simon A, Sikkel MB, Faggian G, Randi AM, Gorelik J, Harding SE, Terracciano CM. Investigation 483 484 of cardiac fibroblasts using myocardial slices. Cardiovasc Res. 2018;114:77-89. 485 14. Watson SA, Duff J, Bardi I, Zabielska M, Atanur SS, Jabbour RJ, Simon A, Tomas A, Smolenski 486 RT, Harding SE, Perbellini F, Terracciano CM. Biomimetic electromechanical stimulation to 487 maintain adult myocardial slices in vitro. Nat Commun. 2019;10:2168. 15. 488 Nunez-Toldra R, Kirwin T, Ferraro E, Pitoulis FG, Nicastro L, Bardi I, Kit-Anan W, Gorelik J, Simon AR, Terracciano CM. Mechanosensitive molecular mechanisms of myocardial fibrosis in 489 490 living myocardial slices. ESC Heart Fail. 2022;9:1400–1412. 491 16. Pitoulis FG, Nunez-Toldra R, Xiao K, Kit-Anan W, Mitzka S, Jabbour RJ, Harding SE, Perbellini F, 492 Thum T, de Tombe PP, Terracciano CM. Remodelling of adult cardiac tissue subjected to 493 physiological and pathological mechanical load in vitro. Cardiovasc Res. 2022;118:814-827. Andreu Z, YÃjñez-MÃ³ M. Tetraspanins in Extracellular Vesicle Formation and Function. 494 17. Front Immunol. 2014;5. 495 496 18. Grossman W, Paulus WJ. Myocardial stress and hypertrophy: a complex interface between 497 biophysics and cardiac remodeling. Journal of Clinical Investigation. 2013;123:3701–3703. 498 19. Travers JG, Kamal FA, Robbins J, Yutzey KE, Blaxall BC. Cardiac Fibrosis. Circ Res. 2016;118:1021-1040. 499 500 20. Wencker D, Chandra M, Nguyen K, Miao W, Garantziotis S, Factor SM, Shirani J, Armstrong RC, Kitsis RN. A mechanistic role for cardiac myocyte apoptosis in heart failure. Journal of 501 502 Clinical Investigation. 2003;111:1497–1504.

medRxiv preprint doi: https://doi.org/10.1101/2024.02.09.24302607; this version posted February 12, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. Nicastro et al. Myocardial -derived sEVs affect remodelling of failing hearts

503 504	21.	Chaitanya GV, Alexander JS, Babu PP. PARP-1 cleavage fragments: Signatures of cell-death proteases in neurodegeneration. Cell Communication and Signaling. 2010;8.
505 506 507	22.	Mohammed SF, Hussain S, Mirzoyev SA, Edwards WD, Maleszewski JJ, Redfield MM. Coronary Microvascular Rarefaction and Myocardial Fibrosis in Heart Failure With Preserved Ejection Fraction. <i>Circulation</i> . 2015;131:550–559.
508 509	23.	Zeng H, Chen J-X. Microvascular Rarefaction and Heart Failure With Preserved Ejection Fraction. <i>Front Cardiovasc Med</i> . 2019;6.
510 511 512 513 514	24.	Huebsch N, Loskill P, Mandegar MA, Marks NC, Sheehan AS, Ma Z, Mathur A, Nguyen TN, Yoo JC, Judge LM, Spencer CI, Chukka AC, Russell CR, So P-L, Conklin BR, Healy KE. Automated Video-Based Analysis of Contractility and Calcium Flux in Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes Cultured over Different Spatial Scales. <i>Tissue Eng Part C Methods</i> . 2015;21:467–479.
515 516	25.	Oh JG, Lee P, Gordon RE, Sahoo S, Kho C, Jeong D. Analysis of extracellular vesicle miRNA profiles in heart failure. <i>J Cell Mol Med</i> . 2020;24:7214–7227.
517 518 519 520	26.	Loyer X, Zlatanova I, Devue C, Yin M, Howangyin K-Y, Klaihmon P, Guerin CL, Kheloufi M, Vilar J, Zannis K, Fleischmann BK, Hwang DW, Park J, Lee H, Menasché P, Silvestre J-S, Boulanger CM. Intra-Cardiac Release of Extracellular Vesicles Shapes Inflammation Following Myocardial Infarction. <i>Circ Res.</i> 2018;123:100–106.
521 522	27.	Sahoo S, Losordo DW. Exosomes and Cardiac Repair After Myocardial Infarction. <i>Circ Res</i> . 2014;114:333–344.
523 524	28.	Tanai E, Frantz S. Pathophysiology of Heart Failure. In: Comprehensive Physiology. Wiley; 2015. p. 187–214.
525 526 527	29.	Pitoulis F, Watson SA, Dries E, Bardi I, Nunez-Toldra R, Perbellini F, Terracciano CM. Myocardial Slices - A Novel Platform for In Vitro Biomechanical Studies. <i>Biophys J</i> . 2019;116:30a.
528 529 530	30.	Schwinger RH, Böhm M, Koch A, Schmidt U, Morano I, Eissner HJ, Uberfuhr P, Reichart B, Erdmann E. The failing human heart is unable to use the Frank-Starling mechanism. <i>Circ Res</i> . 1994;74:959–969.
531 532	31.	Stienen GJM. Pathomechanisms in heart failure: the contractile connection. <i>J Muscle Res Cell Motil</i> . 2015;36:47–60.
533 534 535	32.	Nunez-Toldra R, Kirwin T, Ferraro E, Pitoulis FG, Nicastro L, Bardi I, Kit-Anan W, Gorelik J, Simon AR, Terracciano CM. Mechanosensitive molecular mechanisms of myocardial fibrosis in living myocardial slices. <i>ESC Heart Fail</i> . 2022;9:1400–1412.
536 537	33.	Hutcheson JD, Aikawa E. Extracellular vesicles in cardiovascular homeostasis and disease. <i>Curr Opin Cardiol</i> . 2018;33:290–297.
538 539 540	34.	Gupta S, Knowlton AA. HSP60 trafficking in adult cardiac myocytes: role of the exosomal pathway. <i>American Journal of Physiology-Heart and Circulatory Physiology</i> . 2007;292:H3052–H3056.

medRxiv preprint doi: https://doi.org/10.1101/2024.02.09.24302607; this version posted February 12, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. Nicastro et al. Myocardial -derived sEVs affect remodelling of failing hearts

541 542 543	35.	Tian C, Gao L, Zimmerman MC, Zucker IH. Myocardial infarction-induced microRNA-enriched exosomes contribute to cardiac Nrf2 dysregulation in chronic heart failure. <i>American Journal of Physiology-Heart and Circulatory Physiology</i> . 2018;314:H928–H939.
544 545	36.	Wang Y, Xie Y, Zhang A, Wang M, Fang Z, Zhang J. Exosomes: An emerging factor in atherosclerosis. <i>Biomedicine & Pharmacotherapy</i> . 2019;115:108951.
546 547	37.	Li N, Rochette L, Wu Y, Rosenblatt-Velin N. New Insights into the Role of Exosomes in the Heart After Myocardial Infarction. <i>J Cardiovasc Transl Res</i> . 2019;12:18–27.
548 549	38.	Emanueli C, Shearn AIU, Angelini GD, Sahoo S. Exosomes and exosomal miRNAs in cardiovascular protection and repair. <i>Vascul Pharmacol</i> . 2015;71:24–30.
550 551 552	39.	Sahoo S, Adamiak M, Mathiyalagan P, Kenneweg F, Kafert-Kasting S, Thum T. Therapeutic and Diagnostic Translation of Extracellular Vesicles in Cardiovascular Diseases. <i>Circulation</i> . 2021;143:1426–1449.
553 554 555 556	40.	Ganesan J, Ramanujam D, Sassi Y, Ahles A, Jentzsch C, Werfel S, Leierseder S, Loyer X, Giacca M, Zentilin L, Thum T, Laggerbauer B, Engelhardt S. MiR-378 Controls Cardiac Hypertrophy by Combined Repression of Mitogen-Activated Protein Kinase Pathway Factors. <i>Circulation</i> . 2013;127:2097–2106.
557 558 559	41.	Oikawa S, Wada S, Lee M, Maeda S, Akimoto T. Role of endothelial microRNA-23 clusters in angiogenesis in vivo. <i>American Journal of Physiology-Heart and Circulatory Physiology</i> . 2018;315:H838–H846.
560 561 562	42.	Xing Y, Hou J, Guo T, Zheng S, Zhou C, Huang H, Chen Y, Sun K, Zhong T, Wang J, Li H, Wang T. microRNA-378 promotes mesenchymal stem cell survival and vascularization under hypoxic–ischemic conditions in vitro. <i>Stem Cell Res Ther</i> . 2014;5:130.
563 564 565	43.	Tan J, Shen J, Zhu H, Gong Y, Zhu H, Li J, Lin S, Wu G, Sun T. miR-378a-3p inhibits ischemia/reperfusion-induced apoptosis in H9C2 cardiomyocytes by targeting TRIM55 via the DUSP1-JNK1/2 signaling pathway. <i>Aging</i> . 2020;12:8939–8952.
566 567 568	44.	Wu F, Wang F, Yang Q, Zhang Y, Cai K, Liu L, Li S, Zheng Y, Zhang J, Gui Y, Wang Y, Wang X, Gui Y, Li Q. Upregulation of miRNA-23a-3p rescues high glucose-induced cell apoptosis and proliferation inhibition in cardiomyocytes. <i>In Vitro Cell Dev Biol Anim</i> . 2020;56:866–877.
569 570	45.	O'Brien J, Hayder H, Zayed Y, Peng C. Overview of microRNA biogenesis, mechanisms of actions, and circulation. Front Endocrinol (Lausanne). 2018;9.
571 572	46.	Kehat I, Molkentin JD. Molecular Pathways Underlying Cardiac Remodeling During Pathophysiological Stimulation. <i>Circulation</i> . 2010;122:2727–2735.
573 574 575	47.	Pitoulis FG, Terracciano CM. Heart Plasticity in Response to Pressure- and Volume-Overload: A Review of Findings in Compensated and Decompensated Phenotypes. <i>Front Physiol</i> . 2020;11.
576 577 578	48.	Gobeil S, Boucher CC, Nadeau D, Poirier GG. Characterization of the necrotic cleavage of poly(ADP-ribose) polymerase (PARP-1): implication of lysosomal proteases. <i>Cell Death Differ</i> . 2001;8:588–594.
579 580	49.	Luxán G, Dimmeler S. The vasculature: a therapeutic target in heart failure? <i>Cardiovasc Res</i> . 2022;118:53–64.

Nicastro et al.

Myocardial -derived sEVs affect remodelling of failing hearts

- 581 50. Brutsaert DL. Cardiac Endothelial-Myocardial Signaling: Its Role in Cardiac Growth, Contractile Performance, and Rhythmicity. Physiol Rev. 2003;83:59–115. 582
- Ahmed RE, Anzai T, Chanthra N, Uosaki H. A Brief Review of Current Maturation Methods for 583 51. Human Induced Pluripotent Stem Cells-Derived Cardiomyocytes. Front Cell Dev Biol. 2020;8. 584
- 52. Hua Z, Lv Q, Ye W, Wong CKA, Cai G, Gu D, Ji Y, Zhao C, Wang J, Yang BB, Zhang Y. Mirna-585 directed regulation of VEGF and other angiogenic under hypoxia. PLoS One. 2006;1. 586
- 587 53. Krist B, Podkalicka P, Mucha O, Mendel M, Sępioł A, Rusiecka OM, Józefczuk E, Bukowska-Strakova K, Grochot-Przeczek A, Tomczyk M, Klóska D, Giacca M, Maga P, Niżankowski R, 588 589 Józkowicz A, Łoboda A, Dulak J, Florczyk-Soluch U. miR-378a influences vascularization in 590 skeletal muscles. Cardiovasc Res. 2020;116:1386–1397.
- 591

Figure legends 592

Figure 1. Characterization of human LMS contractility and human LMS-derived sEVs. A. 593 594 Representative traces of produced force of donor and failing LMS at 25% stretch. B. Active force and C. passive force of human donor and failing hearts after 48 hours culture. N=6 595 Donors and N=9 Failing. Data are presented as mean+/- SEM. Multiple unpaired t-tests. 596 597 *P<0.05. D. Particle size distribution of failing and donor sEVs. N=3 donor sEVs and N=6 failing sEVs. Unpaired t-test. ***P<0.001. E. Nanoview representative image of nanoparticle 598 analysis of failing human sEVs. CD63 (red), CD81 (green), CD9 (blue) and F. Transmission 599 electron microscopy with CD63 immunogold labelling of human donor sEVs (left panel) and 600 zoomed in view (right panel). 601

Figure 2. Human donor sEVs significantly increase the active force produced by human 602 603 failing slices at physiological load. A. Representative traces of the force generated by failing slices treated with donor sEVs and control. B. Active force and C. Passive force of the force-604 stretch relationship of human failing slices treated with donor sEVs. N=5 Failing, N=5 605 Failing+Donor sEVs. For each N, the force-stretch measurements of 3-4 LMS were averaged. 606 Data are presented as mean +/- SEM. Multiple paired t-tests. *P<0.05. 607

Figure 3. Characterization of rat LMS contractility and rat LMS-derived sEVs. A.. 608 Representative images of rat slices stretched at 2.2 and 2.4 µm of SL to recapitulate 609 physiological load and overload, respectively (created in BioRender.com). B. Representative 610 611 trace of contractility of physiological and overloaded slices at 25% stretch. C. active force and **D.** passive force of rat physiological and overloaded slice after 48 hours culture. Data are 612 presented as mean +/- SEM. N=28 physiological and N=19 overloaded slices. 2-Way-ANOVA 613 analysis with Šídák's multiple comparisons test. *P<0.05; **P<0.01. E. Particle size 614 distribution of physiological and overloaded EVs from rat slices. N=16 physiological EVs and 615 616 N=8 overloaded EVs. Unpaired t-test. F. Quantification of internal protein content of EVs from physiological and overloaded slices from rat slices. Data are presented as mean +/-617 SEM. Unpaired t-test. *P<0.05. G. Transmission electron microscopy with CD63 immunogold 618 labelling rat physiological EVs (left panel) and zoomed in view (right panel). 619

Nicastro et al.

Myocardial -derived sEVs affect remodelling of failing hearts

Figure 4. The effect of cardiac sEVs on the force generation of rat living myocardial slices. 620

A. Representative traces of physiological slices treated with physiological sEVs, overloaded 621 sEVs and control. B. Active force and C. Passive force of the force stretch relationship of rat 622 physiological slices treated with physiological sEVs, overloaded sEVs or control (PBS only). 623 N=33 PBS treated LMS, N=11 Physiological sEVs LMS, N=14 Overloaded sEVs LMS. Data are 624 presented as mean +/- SEM. 2-Way ANOVA with Tukey's multiple comparisons test. *P<0.05 625 and **P<0.01 for PBS only vs physiological sEVs, ^^=P<0.01 Physiological sEVs vs overloaded 626 627 sEVs. D. Representative traces of dose-response experiments. E. Active force and F. Passive force of the force stretch relationship of rat overloaded slices treated with 10^7, 10^8, 10^9, 628 10^10 sEVs per slices, or control (overloaded). N=19 overloaded, N= 7 10^7, N= 11 10^8, 629 N=16 10^9, N=3 10^10. Data are presented as mean +/- SEM. 2-Way ANOVA with Tukey's 630 multiple comparisons test. *=P<0.05 overloaded vs 10^9 sEVs, ^^=P<0.01 overloaded vs 631 10^8 sEVs, ##=P<0.01 overloaded vs 10^10 sEVs. 632

Figure 5. The effect of physiological sEVs on the fibrosis of overloaded slices. Figure 5. A. 633 Representative images of physiological, overloaded and overloaded + sEVs slices stained for 634 Caveolin 3, Vimentin and Collagen I. Scale bar 50 µm. Quantification of immunofluorescence 635 636 staining of **B.** Vimentin and **C.** Collagen I. Data are presented as mean +/- SEM. One-Way ANOVA with Tukey's multiple comparisons test.. D. Western Blot quantification of Collagen I 637 expression in physiological, overloaded and overloaded slices+sEVs. One-Way ANOVA with 638 Tukey's multiple comparisons test. E. Western Blot quantification of α -SMA expression in 639 physiological, overloaded and overloaded + sEVs slices. Data are presented as mean +/- SEM. 640 One-Way ANOVA with Tukey's multiple comparisons test. F. mRNA quantification of the 641 expression of major pro-fibrotic markers in physiological, overloaded and overloaded + sEVs 642 slices. Data are presented as mean +/- SEM. One-Way ANOVA with Tukey's multiple 643 comparisons test. =P<0.05, **p<0.01. 644

645

646 Figure 6. The effect of physiological sEVs on the apoptosis of overloaded slices. A. Western Blot quantification of PARP-1 expression in physiological, overloaded and overloaded + sEVs 647 slices. One-Way ANOVA with Tukey's multiple comparisons test. *P<0.05, **P<0.01. B. 648 Western Blot quantification of Bcl-2 expression in physiological, overloaded and overloaded 649 + sEVs slices. One-Way ANOVA with Tukey's multiple comparisons test. **P<0.01. C. 650 Quantification of immunofluorescence staining of TUNEL assay in physiological, overloaded 651 and overloaded slices+ sEVs. Slices were stained with DAPI, Isolectin B4, TUNEL and WGA. 652 One-Way ANOVA with Tukey's multiple comparisons test. *=P<0.05. Scale bar 50 μ m. 653

654

Figure 7. The effect of physiological sEVs on the blood vessel rarefaction in overloaded 655 slices. A. Quantification of Isolectin B4 immunostaining in physiological, overloaded and 656 overloaded slices + sEVs. Scale bar 50 μ m. Data are presented as mean +/- SEM. One-Way 657 ANOVA with Tukey's multiple comparisons test. **P<0.01, ****P<0.0001. B. Quantification 658 of VEGF gene expression by qPCR in physiological, overloaded and overloaded + sEVs slices. 659 660 Data are presented as mean +/- SEM. One-Way ANOVA with Tukey's multiple comparisons test. over physiological slices. *P<0.05. Data are expressed as fold change expression. 661

Figure 8. The effect of physiological sEVs on iPSC-CMs and on iPSC-CMs cultured with 662 microvasculature endothelial cells. A. Representative traces of calcium transients in iPSC-663

Nicastro et al.

Myocardial -derived sEVs affect remodelling of failing hearts

CMs treated with physiological sEVs and control. B. Representative traces of contractility in 664 iPSC-CMs treated with physiological sEVs and control C. Amplitude D. Time to peak E. Time 665 to 50% decay and F. Time to 80% decay of calcium transients and G. amplitude of 666 contractility in iPSC-CMs treated with rat physiological sEVs or control. Unpaired t-test. 667 *=P<0.05. H. Representative traces of calcium transient amplitude in iPSC-CMs and 668 microvasculature ECs co-culture treated with physiological sEVs and control. I. 669 Representative traces of contractility in iPSC-CMs and microvasculature ECs co-culture 670 treated with physiological sEVs and control J. Amplitude K. Time to peak L. Time to 50% 671 decay and M. Time to 80% decay of calcium transients and N. amplitude of contractility in 672 iPSC-CMs co-cultured with microvasculature endothelial cells treated with rat physiological 673 sEVs or control. Data are presented as mean +/- SEM. Unpaired t-test. *P<0.05. 674

Figure 1

0.2 µm



0.2 µm









Figure 5



Figure 6



Figure 7





В



